Literature DB >> 2161898

Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line.

C O Zachariae1, A O Anderson, H L Thompson, E Appella, A Mantovani, J J Oppenheim, K Matsushima.   

Abstract

A monocyte chemotactic and activating factor (MCAF) has been purified from TNF-stimulated 8387 human fibrosarcoma cell line-conditioned media. The purified MCAF showed microheterogeneity yielding two bands on SDS-PAGE analysis. Fibrosarcoma-derived MCAF specifically competed with THP-1 (a human monocytic cell line)-derived 125I-labeled MCAF in binding to human PBMC, whereas a similar basic heparin-binding leukocyte chemoattractant, IL-8, did not. The purified MCAF stimulated superoxide anion and N-acetyl beta-D glucosaminidase-releasing activity in human monocytes, as well as monocyte cytostatic augmenting activity against tumor cells and chemotactic activity for monocytes. When injected subcutaneously into Lewis rat ears, the purified human MCAF also induced considerable in vivo local monocyte infiltration beginning at 3 h and becoming maximal at 18 h. In conclusion, the data presented in this paper indicate that MCAF is a potent activator of monocytes as well as a monocyte recruitment factor that acts through receptors that are specific for this novel molecule. This novel cytokine might have an important role in tumor growth control due to its ability to attract and activate monocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161898      PMCID: PMC2187957          DOI: 10.1084/jem.171.6.2177

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Production of monocyte chemotactic and activating factor (MCAF) by human dermal fibroblasts in response to interleukin 1 or tumor necrosis factor.

Authors:  C G Larsen; C O Zachariae; J J Oppenheim; K Matsushima
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

2.  Properties of a specific interleukin 1 (IL 1) receptor on human Epstein Barr virus-transformed B lymphocytes: identity of the receptor for IL 1-alpha and IL 1-beta.

Authors:  K Matsushima; T Akahoshi; M Yamada; Y Furutani; J J Oppenheim
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

3.  Coexistence of a chemotactic factor and a retroviral P15E-related chemotaxis inhibitor in human tumor cell culture supernatants.

Authors:  J M Wang; G J Cianciolo; R Snyderman; A Mantovani
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

4.  Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF).

Authors:  Y Furutani; H Nomura; M Notake; Y Oyamada; T Fukui; M Yamada; C G Larsen; J J Oppenheim; K Matsushima
Journal:  Biochem Biophys Res Commun       Date:  1989-02-28       Impact factor: 3.575

5.  Production and characterization of recombinant human neutrophil chemotactic factor.

Authors:  R Furuta; J Yamagishi; H Kotani; F Sakamoto; T Fukui; Y Matsui; Y Sohmura; M Yamada; T Yoshimura; C G Larsen
Journal:  J Biochem       Date:  1989-09       Impact factor: 3.387

6.  Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader.

Authors:  E Pick; D Mizel
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

7.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

  7 in total
  55 in total

1.  Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis.

Authors:  T D Duensing; J S Wing; J P van Putten
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

3.  The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours.

Authors:  M G Luciani; A Stoppacciaro; G Peri; A Mantovani; L P Ruco
Journal:  Mol Pathol       Date:  1998-10

4.  Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1.

Authors:  B Johnston; A R Burns; M Suematsu; T B Issekutz; R C Woodman; P Kubes
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 5.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

6.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.

Authors:  B J Rollins; M E Sunday
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

7.  The human cytokine I-309 is a monocyte chemoattractant.

Authors:  M D Miller; M S Krangel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

8.  Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.

Authors:  T Asano; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.

Authors:  E Robinson; E C Keystone; T J Schall; N Gillett; E N Fish
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

Review 10.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.